RTX-321

N/A

Report date: 2023/04/17 16:24:22

Base Information

Drug NameRTX-321
Drug Alias NameA cellular therapy that expresses 4-1BBL, IL-12, and HPV-16 Antigen(Rubius)RTX-321RCT-aAPCRTX-aAPC HPV
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9Interleukin-12 modulatorsProtein E7 modulators
TargetsTumor necrosis factor receptor superfamily member 9Interleukin-12Protein E7
Therapy Area/IndicationsUterine Cervical NeoplasmsHead and Neck NeoplasmsAnus Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRubius Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRubius Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsHead and Neck NeoplasmsAnus Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A